↑ Roth, BL; Driscol, J.PDSP Ki Database(неопр.).Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health(12 January 2011).Проверено 4 ноября 2013.Архивировано 8ноября 2013года.
↑ Monachon MA, Burkard WP, Jalfre M, Haefely W (1972). “Blockade of central 5-hydroxytryptamine receptors by methiothepin”. Naunyn Schmiedebergs Arch. Pharmacol. 274 (2): 192—7. DOI:10.1007/BF00501854. PMID4340797.
↑ Goetz AS, King HK, Ward SD, True TA, Rimele TJ, Saussy DL (January 1995). “BMY 7378 is a selective antagonist of the D subtype of alpha 1-adrenoceptors”. European Journal of Pharmacology. 272 (2–3): R5—6. DOI:10.1016/0014-2999(94)00751-R. PMID7713154.
↑ Farré, M; Roset, PN; Llorente, M; Márquez, M; Albet, C; Pérez, JA; Herrero, E; Ortíz, JA (1997). “Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration”. Methods and findings in experimental and clinical pharmacology. 19 (5): 343—50. PMID9379783.
↑ Montiel, C; Herrero, CJ; García-Palomero, E; Renart, J; García, AG; Lomax, RB (1997). “Serotonergic effects of dotarizine in coronary artery and in oocytes expressing 5-HT2 receptors”. European Journal of Pharmacology. 332 (2): 183—93. DOI:10.1016/S0014-2999(97)01073-X. PMID9286620.
↑ Rényi L, Larsson LG, Berg S, Svensson BE, Thorell G, Ross SB. (1991). “Biochemical and behavioural effects of isamoltane, a beta-adrenoceptor antagonist with affinity for the 5-HT1B receptor of rat brain”. Naunyn Schmiedebergs Arch Pharmacol. 343 (1): 1—6. DOI:10.1007/bf00180669. PMID1674359.
↑ Waldmeier PC, Williams M, Baumann PA, Bischoff S, Sills MA, Neale RF. (1988). “Interactions of isamoltane (CGP 361A), an anxiolytic phenoxypropanolamine derivative, with 5-HT1 receptor subtypes in the rat brain”. Naunyn Schmiedebergs Arch Pharmacol. 337 (6): 609—620. DOI:10.1007/bf00175785. PMID2905765.
↑ Foong JP, Bornstein JC. (2009). “5-HT antagonists NAN-190 and SB 269970 block alpha2-adrenoceptors in the guinea pig”. Neuroreport. 20 (3): 325—330. DOI:10.1097/WNR.0b013e3283232caa. PMID19190523.
↑ Bell, R; Hobson, H (1993). “Effects of pindobind 5-hydroxytryptamine1A (5-HT1A), a novel and potent 5-HT1A antagonist, on social and agonistic behaviour in male albino mice”. Pharmacology, Biochemistry, and Behavior. 46 (1): 67—72. DOI:10.1016/0091-3057(93)90318-N. PMID8255924.
↑ Jerning E, Svantesson GT, Mohell N. (1998). “Receptor binding characteristics of [3H]NAD-299, a new selective 5-HT1A receptor antagonist”. Eur J Pharmacol. 360 (2–3): 219—225. DOI:10.1016/S0014-2999(98)00667-0. PMID9851589.
↑ Starr KR, Price GW, Watson JM, Atkinson PJ, Arban R, Melotto S, Dawson LA, Hagan JJ, Upton N, Duxon MS. (2007). “SB-649915-B, a novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test”. Neuropsychopharmacology. 32 (10): 2163—2172. DOI:10.1038/sj.npp.1301341. PMID17356576.
↑ Czoty PW, Howell LL (October 2000). “Behavioral effects of AMI-193, a 5-HT(2A)- and dopamine D(2)-receptor antagonist, in the squirrel monkey”. Pharmacology, Biochemistry, and Behavior. 67 (2): 257—64. DOI:10.1016/S0091-3057(00)00321-X. PMID11124389.
↑ Luparini MR, Garrone B, Pazzagli M, Pinza M, Pepeu G (November 2004). “A cortical GABA-5HT interaction in the mechanism of action of the antidepressant trazodone”. Progress in Neuro-psychopharmacology & Biological Psychiatry. 28 (7): 1117—27. DOI:10.1016/j.pnpbp.2004.05.046. PMID15610924.
↑ Hamada K, Yoshida M, Isayama H, Yagi Y, Kanazashi S, Kashihara Y, Takeuchi K, Yamaguchi I (November 2007). “Possible involvement of endogenous 5-HT in aggravation of cerulein-induced acute pancreatitis in mice”. Journal of Pharmacological Sciences. 105 (3): 240—50. DOI:10.1254/jphs.FP0071049. PMID17965538.
↑ Björk L, Cornfield LJ, Nelson DL, Hillver SE, Andén NE, Lewander T, Hacksell U. (1991). “Pharmacology of the novel 5-hydroxytryptamine1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: inhibition of (R)-8-hydroxy-2-(dipropylamino)tetralin-induced effects”. J Pharmacol Exp Ther. 258 (1): 58—65. PMID1830099.
↑ Cliffe IA, Brightwell CI, Fletcher A; et al. (May 1993). “(S)-N-tert-butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: a selective antagonist at presynaptic and postsynaptic 5-HT1A receptors”. Journal of Medicinal Chemistry. 36 (10): 1509—10. DOI:10.1021/jm00062a028. PMID8496920.
↑ A. Fletcher, E. A. Forster, D. J. Bill, G. Brown, I. A. Cliffe, J. E. Hartley, D. E. Jones, A. McLenachan, K. J. Stanhope, D. J. Critchley, K. J. Childs, V. C. Middlefell, L. Lanfumey, R. Corradetti, A. M. Laporte, H. Gozlan, M. Hamon & C. T. Dourish (1996). “Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist”. Behavioural Brain Research. 73 (1–2): 337—333. DOI:10.1016/0166-4328(96)00118-0. PMID8788530.
↑ Dedeoğlu, A; Fisher, LA (1991). “Central and peripheral injections of the 5-HT2 agonist, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane, modify cardiovascular function through different mechanisms”. The Journal of Pharmacology and Experimental Therapeutics. 259 (3): 1027—34. PMID1762059.
↑ Baker, BJ; Duggan, JP; Barber, DJ; Booth, DA (1988). “Effects of dl-fenfluramine and xylamidine on gastric emptying of maintenance diet in freely feeding rats”. European Journal of Pharmacology. 150 (1—2): 137—42. DOI:10.1016/0014-2999(88)90759-5. PMID3402534.
Другой контент может иметь иную лицензию. Перед использованием материалов сайта WikiSort.ru внимательно изучите правила лицензирования конкретных элементов наполнения сайта.
2019-2025 WikiSort.ru - проект по пересортировке и дополнению контента Википедии